Fused bicyclic inhibitors of HCV

Details Fused bicyclic inhibitors of HCV Fused bicyclic inhibitors of HCV

2006-03-27

2011-10-04

Spivack, Phyllis G (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S279000

Reexamination Certificate

active

08030318

ABSTRACT:
Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.

REFERENCES:
patent: 3873545 (1975-03-01), Osselaere et al.
patent: 6476031 (2002-11-01), Chakravarty et al.
patent: 2004/0032430 (2004-02-01), Yung et al.
patent: 2004/0038856 (2004-02-01), Chakravarty et al.
patent: 2004/0132159 (2004-07-01), Zhong et al.
patent: 2005/0004143 (2005-01-01), Dugar et al.
patent: 2007/0155716 (2007-07-01), Simmen et al.
patent: 2009/0131460 (2009-05-01), Simmen et al.
patent: 2009/0156595 (2009-06-01), Raboisson et al.
patent: 2 295 387 (1996-05-01), None
patent: 2003/321472 (2003-11-01), None
patent: WO-95/19774 (1995-07-01), None
patent: WO-00/12497 (2000-03-01), None
patent: WO-01/047921 (2001-07-01), None
patent: WO-02/22601 (2002-03-01), None
patent: WO-02/076976 (2002-10-01), None
patent: WO-03/059913 (2003-07-01), None
patent: WO-03/077921 (2003-09-01), None
patent: WO-03/078423 (2003-09-01), None
patent: WO-03/078426 (2003-09-01), None
patent: WO-03/078427 (2003-09-01), None
patent: WO 03/097615 (2003-11-01), None
patent: WO-2004/020584 (2004-03-01), None
patent: WO-2004/024159 (2004-03-01), None
patent: WO 2004/047818 (2004-06-01), None
patent: WO-2004/048930 (2004-06-01), None
patent: WO-2004/065392 (2004-08-01), None
patent: WO-2004/074270 (2004-09-01), None
patent: WO-2004/087056 (2004-10-01), None
patent: WO 2005/032481 (2005-04-01), None
patent: WO 2006/100310 (2006-09-01), None
patent: WO-2006/105063 (2006-10-01), None
Murata et al. (Virology, vol. 331, pp. 407-417; 2005).
Stella (Expert Opinion on Therapeutic Patents, Prodrugs as therapeutics, col. 14, No. 3, pp. 277-280; 2004).
Wolff (Burger's Medicinal Chemistry, 5th Ed., vol. 1, pp. 975-977; 1994).
Testa (Biochemical Pharmacology, Prodrug Research: futile or fertile?, vol. 68, pp. 2097-2106; 2004).
Ettmayer et al. (Medicinal Chemistry, Lessons Learned from Marketed and Investigational Prodrugs, vol. 47, No. 10, pp. 2394-2404; 2004).
Cheng et al. (Oncogene, vol. 23, pp. 7821-7838; 2004).
N. Dumont, et al., Transforming Growth Factor-β and Breast Cancer Tumor Promoting Effects of Transforming Growth Factor-β,Breast Cancer Research,2(2):125-132, 2000.
M. de Caestecker, et al., Role of Transforming Growth Factor-β Signaling in Cancer,Journal of the National Cancer Institute,92(17):I388-1402, 2000.
J. Munger, et al., The Integrin αvβ6 Binds and Activates Latent TGFβ1 : A Mechanism for Regulating Pulmonary Inflammation and Fibrosis,Cell,96:319-328, 1999.
S. Crawford, et al., Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo;Cell93:1159-1170, 1998.
R. Lyons, et al., Transforming Growth Factors and the Regulation of Cell Proliferation,Eur. J. Biochem,187:467-473, 1990.
T. Kimura, et al., Association of Transforming Growth Factor-β1 Functional Polymorphisms with Natural Clearance of Hepatitis C Virus,Brief Report,193:1371-1374, 2006.
G. Breipohl, et al., Novel Synthetic Routes to PNA Monomers and PNA-DNA Linker Molecules,Tetrahedron,53(43):14671-14686, 1997.
Q. Choo, et al., Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome,Science,244:359-362, 1989.
C. Cywin, et al., Discovery and SAR of Novel [1,6]Naphthyridines as Potent Inhibitors of Spleen Tyrosine Kinase (SYK),Bioorganic & Medicinal Chemistry Letters,13:1415-1418, 2003.
D. Harrison, et al., The Synthesis of Some Cyclic Hydroxamic Acids from o-Aminocarboxylic Acids,Journal of the Chemical Society Abstracts,XP002373945, Database accession No. 1960: 118360, 2157-2160, 1960.
W. Kim, The Burden of Hepatitis C in the United States,Hepatology,36(5): Suppl. 1:S30-S34, 2002.
A. Kolykhalov, et al., Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo,Journal of Virology,74(4):2046-2051, 2000.
N. Krieger, et al., Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations,Journal of Virology,75(10):4614-4624, 2001.
G. Lauer, et al., Hepatitis C Virus Infection,N. Engl J Med,345(I):41-52, 2001.
V. Lohmann, et al., Replications of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line,Science,285:110-113, 1999.
S. Nishikawa, et al., Cytokinin Activity of 4-Aminopyridopyrimidines Towards the Growth of Tobacco Callus,Biosci. Biotech. Biochem.,58(9):1709-1710, 1994.
H. Wamhoff, Dihalogentriphenylphosphorane in der heterocyclensynthese, 29. Eine einfache Synthese von Pteridin-4-onen aus 3-Amino-2-pyrazincarbonsäuremethylester and Pyrazino[3,1]oxazin-4-onen, Synthesis, 405-410, 1994. (English Language Abstract).
B. Verecek, et al., Neighboring Group Interaction in Ortho-Substituted Heterocycles.2. 1,2,4- Oxadiazolylpyridines and Pyrido[2,3-d]pyrimidine 3-Oxides,J. Org. Chem.,44(10):1695-1699, 1979.
National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-Jun. 10-12, 2002,Hepatology,S3-S20, 2002.
T. Sekiguchi, et al., Reduction of Virus Burden-Induced Splenectomy in Patients With Liver Cirrhosis Related to Hepatitis C Virus Infection,World J. Gastroenterol,12(13):2089-2094, 2006.
M. De Mitri, et al., HCV-Associated Liver Cancer Without Cirrhosis,Lancet,Abstract: 345(8947), 1995.
M. Nogradi, Dimethyl-β-Cyclodextrin,Drugs of the Future,9(8):577-578, 1984.
K. Cooper, et al., Bicyclo[3.3.0]octenones in Synthesis. An Approach to the Synthesis of the Antitumor Sesquiterpene Quadrone,J. Chem. Soc. Perkin Trans.,1:799-809; 1984.
P. Dowd, et al., Free Radical Ring-Expansion Leading to Novel Six- and Seven-Membered Heterocycles,Tetrahedron,47(27):4847-4860, 1991.
M. Greco, et al., Highly Stereoselective Synthesis of Substituted Hydrindanes Related to the Antiepileptic Drug Topiramate,Tetrahedron Letters,33(35):5009-5012, 1992.
M. Moyer. et al., Intramolecular N-H, O-H and S-H Insertion Reactions. Synthesis of Heterocycles from α-Diazo β-Keto Esters,J. Org. Chem.,50:5223-5230, 1985.
M. Wolff, et al., Thia. Steriods. III. Derivatives of 2-Thia-A-nor-5α-androstan-17β-ol As Probes of Steriod-Receptor Interactions,Journal of Medicinal Chemistry,I3(3):531-534, 1970.
Dorwald, Side Reactions in Organic Synthesis,Wiley-VCH, Weinheim,p. IX of Preface, 2005.
J Massagué, The Transforming Growth Factor-β Family,Annu Rev Cell Biol.,6:597-641, 1990.
A. Roberts, et al., Transforming Growth Factor-βs,Handbook of Experimental Pharmacology,95:419-459, 1990.
S. Wahl, et al., Inflammatory and Immunomodulatory Roles of TGF-β,Immunol. Today,10(8):258-261, 1989.
D. Lawrence, Transforming Growth Factor-β: A General Review,Euro. Cytokine Network,7(3):363-374, 1996.
J. Munger, et al., Latent Transforming Growth Factor-β: Structural Features and Mechanisms of Activation,Kidney International,51:1376-1382, 1997.
J Massagué, Receptors for the TGF-β Family,Cell,69: 1067-1070, 1992.
X Wang, et al., Expression Cloning and Characterization of the TGF-β Type III Receptor,Cell,67:797-805, 1991.
F. Lopez-Casillas, Structure and Expression of the Membrane Proteoglycan Betaglycan, a Component of the TGF-β Receptor System,Cell,67:785-795, 1991.
J. Wrana, et al., TGFβ Signals Through a Heteromeric Protein Kinase Receptor Complex,Cell,71:1003-1014,1992.
H. Lin, et al., Expression Cloning of the TGF-β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase,Cell,68:775-785, 1992.
J Massagué, TGF-β Signal Transduction,Annu. Rev. Biochem.,67: 753-791, 1998.
Goodman and Gilman's, The Pharmacological Basis of Therapeutics: Biotransformation of Drugs,8thEd., Pergamon Press,13-15, 1990.

Affiliated with

Also associated with

Rating

Fused bicyclic inhibitors of HCV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused bicyclic inhibitors of HCV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused bicyclic inhibitors of HCV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4283486